ECI Technology, Inc. – Trademark Portfolio
Entity Type: 03
ECI Technology, Inc. holds 17 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 9 (Computers & Electronics) — 13 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 4 Nice Classification classes. Currently, 10 trademarks are registered. Notable registered marks include LIBRA, PRIMA, RECIPAK, CHEMPACK, and QUALI-FILL. The owner is based in Houston, TX.
10801 Hammerly #240
Houston, TX 77043
Showing of trademarks Trademarks
Trademark Classifications
ECI Technology, Inc.'s trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Scientific and technological services; industrial analysis and research services
Frequently Asked Questions
How many trademarks does ECI Technology, Inc. have?
ECI Technology, Inc. has 17 U.S. trademarks filed with the USPTO. Of these, 10 registered, 3 abandoned, 4 cancelled.
What trademark classes does ECI Technology, Inc. file in?
ECI Technology, Inc. files trademarks across 4 Nice Classification classes. The most active classes are Class 9 (Computers & Electronics), Class 42 (Computer & Scientific), Class 37 (Building & Construction), Class 1 (Chemicals). Class 9 covers scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments.
What are ECI Technology, Inc.'s most well-known trademarks?
ECI Technology, Inc.'s registered trademark portfolio includes well-known marks such as LIBRA, PRIMA, RECIPAK, CHEMPACK, and QUALI-FILL. These are among 10 currently registered trademarks in the portfolio.
What is ECI Technology, Inc.'s trademark registration success rate?
ECI Technology, Inc. has a 59% trademark registration rate, with 10 out of 17 resolved applications resulting in successful registration. Currently, 0 applications are pending review.